Sign in
Taking people in United StatesNo phase

Studies markers that may predict myeloma in people with early plasma cell conditions

Observes people with early plasma cell disorders to find markers of progression to myeloma.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Status
Recruiting
People taking part
200 people, planned
Started
14 Dec 2015
Expected to end
30 Apr 2028
Type of study
Observational
Treatments tested
  • Biospecimen Collection
  • Laboratory Biomarker Analysis
Record updated
7 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with MGUS or smoldering multiple myeloma who have no symptoms. Researchers want to learn which patients later develop multiple myeloma.

Age
18 years or older
Sex
All sexes can join
Disease stage
Monoclonal gammopathy of unknown significance (MGUS): serum monoclonal protein < 3 g/dL or urinary monoclonal protein < 500 mg per 24 hours, and clonal bone marrow plasma cells < 10%. Smoldering multiple myeloma: serum monoclonal protein >= 3 g/dL or urinary monoclonal protein >= 500 mg per 24 hours and/or clonal bone marrow plasma cells 10-60%. For both: no myeloma defining events or amyloidosis.
Earlier treatment
No earlier or current systemic treatment for the symptom-free gammopathy. Bisphosphonates are allowed. Radiotherapy, chemotherapy and investigational drugs are not allowed.

Main reasons for not taking part

  • Signs of myeloma defining events, such as high calcium, kidney problems, anemia or bone lesions
  • Clonal bone marrow plasma cells of 60% or more
  • Plasma cell leukemia
  • Uncontrolled other illness, such as active infection or psychiatric illness that would make taking part difficult

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients with monoclonal gammopathy of unknown significance. Both criteria must be met:; Serum monoclonal protein < 3 g/dL or urinary monoclonal protein < 500 mg per 24 hours and clonal bone marrow plasma cells < 10%; Absence of myeloma defining events or amyloidosis
  • Patients with smoldering multiple myeloma. Both criteria must be met:; Serum monoclonal protein >= 3 g/dL or urinary monoclonal protein >= 500 mg per 24 hours and/or clonal bone marrow plasma cells 10-60%; Absence of myeloma defining events or amyloidosis

Who cannot take part

  • Prior or concurrent systemic treatment for asymptomatic monoclonal gammopathies; Bisphosphonates are permitted; Radiotherapy is not permitted; Prior treatment with chemotherapy or investigational agents for asymptomatic gammopathies is not permitted
  • Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness/social situations that would compromise compliance with study requirements
  • Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following; Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL); Renal Insufficiency: creatinine clearance < 40 ml/min or serum creatinine > 2 mg/dL; Anemia: hemoglobin value < 10 g/dL or 2 g/dL < normal reference; Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography CT (PET-CT); Clonal bone marrow plasma cell percentage >= 60%; Involved:uninvolved serum free light chain ratio >= 100 measured by Freelite assay (The Binding Site Group, Birmingham, United Kingdom [UK]); > 1 focal lesions on magnetic resonance imaging (MRI) studies (each focal lesion must be 5 mm or more in size)
  • Plasma cell leukemia

Where in United States

  • M D Anderson Cancer CenterHouston, United StatesContact: Mei HuangTaking people

About the trial

What the trial wants to find out

The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.

The group in the trial

  • Observational (biospecimen collection)

    Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.

    Treatment: Biospecimen Collection and Laboratory Biomarker Analysis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma (ORIGIN Study)
Plain-language title
Studies markers that may predict myeloma in people with early plasma cell conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
7 October 2026